<DOC>
	<DOCNO>NCT03071848</DOCNO>
	<brief_summary>This study evaluate safety bevacizumab ( Avastin® ) combine standard chemotherapy participant advance cervical cancer , special focus incidence gastrointestinal ( GI ) genitourinary ( GU ) fistulas GI perforation common practice setting .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Bevacizumab Combination With Paclitaxel Cisplatin/Carboplatin Toptecan Participants With Advanced Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age 18 old Diagnosis primary stage IVB , recurrent persistent squamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix amenable curative treatment surgery and/or radiation therapy Retrospective clinical decision make initiate therapy bevacizumab ( Avastin® ) combine standard chemotherapy ( cisplatin carboplatin topotecan paclitaxel ) 01 January 2015 01 January 2016 All participant must receive least one dose bevacizumab combine standard chemotherapy 01 January 2015 01 January 2016 AND least 12 month document follow , treatment start , unless die lose follow within minimum study entry follow period Availability documentation advance cervical cancer ( include prior treatment applicable ) follow participant 's medical record Participation study period interventional clinical trial interventional study may impact advanced cervical cancer outcome Participants receive prior therapy antiVEGF drug , include bevacizumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>